Year: 2019

VANCOUVER, Colombie-Britannique, 19 déc. 2019 (GLOBE NEWSWIRE) — AgraFlora Organics International Inc.  (« AgraFlora » ou la « Société ») (CSE : AGRA) (Frankfurt: PU31) (OTCPK : AGFAF) une société internationale de cannabis diversifiée et axée sur la croissance est heureuse d’annoncer qu’elle est en train de concevoir les points de vente de cannabis au détail suivants sur ses sites de culture :un point de vente au détail de 1 200 pieds carrés adjacent à son installation de culture et de transformation autorisée de 37 000 pieds carrés située à Scarborough, en Ontario ; et,un point de vente au détail de 690 pieds...

– Selecta eligible to receive upfront and milestone payments of over $240 million –– AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and potentially enable re-treatment of patients with Pompe disease –WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2019 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced that the companies have entered into a license agreement. Under the terms of the agreement, AskBio has exercised its option to exclusively license rights to develop and commercialize Selecta’s immune tolerance platform, ImmTOR, for use in adeno-associated virus (AAV) gene therapy for the treatment of Pompe disease. When used in combination with AAV gene therapy...

SAN JOSE, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) — Calix, Inc. (NYSE: CALX) today announced that more than 75 communications service providers (CSPs) worldwide are deploying its 10G solutions. The versatility of the AXOS® platform and the everyPON strategy, enable CSPs to simplify their networks and operations with the technology of their choice. Coupled with Calix Marketing Cloud, CSPs can accurately identify subscribers ready for 10G PON services and ensure they are deploying the ideal PON technology to deliver the desired experience.Calix AXOS is the only software access platform with a portfolio of systems that will power networks built on all PON technologies—GPON, XGS-PON, 10G EPON, and NG-PON2. The E7-2 Intelligent Modular System and the E9-2 Intelligent Edge System both offer the scalability to grow networks...

NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) — FTE Networks, Inc. (NYSE American: FTNW) (“FTE” or the “Company”) announced that on December 17, 2019 it received a letter from the NYSE American LLC (the “Exchange”) notifying the Company that the Exchange had determined to commence proceedings to delist the Company’s common stock (the “Common Stock”) from the Exchange, pursuant to Section 1003(f)(iii) of the NYSE American Company Guide (the “Company Guide”) because the Company or its management have engaged in operations that, in the opinion of the Exchange, are contrary to the public interest. The common stock was suspended at market close on NYSE American on the same date.The Exchange stated that it will apply to the Securities and Exchange Commission (the “SEC”)...

– Top-line statistical results expected mid-2020 –– Company to meet with FDA in January 2020 regarding Phase 3 clinical development plan –WATERTOWN, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced the completion of patient enrollment in the six-month, head-to-head, Phase 2 COMPARE clinical trial. The trial enrolled 150 patients across 49 sites trial and is evaluating the superiority of a once-monthly dose of Selecta’s lead product candidate, SEL-212 (ImmTOR + pegadricase), versus a bi-weekly dose of pegloticase, the current FDA-approved uricase therapy for adult patients with chronic refractory...

FARMINGTON HILLS, Mich., Dec. 19, 2019 (GLOBE NEWSWIRE) — Level One Bancorp, Inc. (NASDAQ: LEVL) (“Level One”) announced today that it has issued $30.0 million aggregate principal amount of fixed-to-floating rate subordinated notes (the “Notes”) in a private placement transaction.  Level One intends to use the net proceeds of the offering for general corporate purposes, including partially funding its pending acquisition of Ann Arbor State Bank.The Notes mature December 18, 2029 and bear interest at an initial fixed rate of 4.75% per annum. From and including December 18, 2024 to but excluding the maturity date, the Notes will bear interest at a floating rate, reset quarterly. Level One will be entitled to redeem the Notes, in whole or in part, on any interest payment date on or after December 18,...

 – Wholly-Owned anti-PD-L1 and anti-CD166 Programs Entering Phase 2 Studies –– Partnered Clinical Programs Advancing –– Multiple Updates Anticipated Across Portfolio in 2020 –SOUTH SAN FRANCISCO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today provided an update on its lead programs and 2020 clinical portfolio outlook.“Our clinical pipeline today reflects the continued progress we have made in advancing our two wholly-owned lead programs, CX-072 and CX-2009, from initial clinical proof of concept into Phase 2 clinical development,” said Sean McCarthy, D....

London, December 19, 2019FPT Industrial, the global powertrain brand of CNH Industrial N.V. (NYSE: CNHI / MI: CNHI),  today announced its agreement to acquire 100% of Dolphin N2, a startup specialized in innovative internal combustion engine technology, and a spin-out company from Ricardo plc (LSE: RCDO) – a global and strategic, technical and environmental consultancy company specialized in the transport, energy and scarce resources sectors.With this acquisition, FPT Industrial aims to advance this expertise, substantially increasing fuel efficiency while reducing operating costs and CO2 emissions, initially for long-haul trucks and other heavy-duty applications. This technology could also be extended to other industrial segments across the complete power range, and will be suitable for all fuels, with ad hoc configuration...